Subscribe or Manage Preferences

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA

VBCR - December 2017, Vol 6, No 5 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.

In this trial, patients with RA who were inadequate responders to MTX alone were initially treated with MTX (≥15 mg/week orally) plus subcutaneous tocilizumab 162 mg either weekly (qw; patients ≥100 kg) or every 2 weeks (q2w; patients <100 kg). Dose escalation from q2w to qw dosing was indicated in patients who had not achieved LDA (Disease Activity Score 28 [DAS28] ≤3.2) at week 12. Patients who achieved DAS28–erythrocyte sedimentation rate (DAS28-ESR) ≤3.2 at week 24 were randomized 1:1 to receive tocilizumab monotherapy or tocilizumab plus MTX until week 52 (double blind).

The primary outcome was comparison of the mean change in DAS28-ESR score from week 24 to week 40 between the tocilizumab monotherapy and tocilizumab plus MTX groups (noninferiority margin of 0.6). At week 24, patients (n = 294) were randomized to receive tocilizumab monotherapy (n = 147) or tocilizumab plus MTX (n = 147). The mean age of the study population was 55.5 years; the majority (74.8%) were female. The mean RA disease duration was 6.8 years, with a mean DAS28-ESR of 6.3. At week 24, prior to randomization, DAS28 scores were similar in both groups.

The primary efficacy analysis showed that, from week 24 to week 40, the mean change in DAS28 was 0.46 in the tocilizumab monotherapy group and 0.14 in the tocilizumab plus MTX group. A higher proportion of patients had DAS28-ESR worsening ≥1.2 in the tocilizumab plus MTX cohort versus the tocilizumab monotherapy cohort from week 24 to week 40 (28.6% vs 21.1%), which was similar at week 52 (29.9% vs 26.5%).

The authors concluded that patients receiving tocilizumab plus MTX who achieve LDA may discontinue MTX and maintain disease control with tocilizumab monotherapy.

Source: Kremer J, Rigby WFC, Singer N, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized controlled trial. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 1905.

Related Items
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Suboptimal EHR Reporting of Clinical Measures in Patients with RA Receiving a Biologic or Targeted Synthetic DMARD
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Tocilizumab Monotherapy as Effective as TNF Inhibitors plus MTX in Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Both Tofacitinib and Baricitinib in Combination with MTX Are Efficacious in Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: January 15, 2018
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology